Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, somapacitan (Sogroya ®) cannot be endorsed for use within NHS Wales for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD). |
||
|
||
Medicine details |
||
| Medicine name | somapacitan (Sogroya®) | |
| Formulation | 10 mg/1.5 mL solution for injection in pre-filled pen | |
| Reference number | 3505 | |
| Indication | Replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD) |
|
| Company | Novo Nordisk Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/02/2022 | |